RV 403
Status:Planned
Phase:II
Principal Investigator(s):Hannah Kibuuka
Objective:Assess the safety, reactogenicity, and tolerability of the vaccination regimens.
Prevention Option(s):HIV Vaccine
Study Design:Randomized
Arms and Assigned Interventions
Description
Mode of Delivery
ARMs
Trial Sponsors:
US Surgeon General/Dept. of the Army
Start Date
End Date
June 30, 2015
none
Enrollment:210
Age range:
18 Years ↔
40 Years
Population: